Cell Cytotoxicity Screening & Profiling Services

Small Molecule Cell Cytotoxicity Assays

Understanding cell cytotoxicity, either as a result of targeted therapy or as a side effect, is important in drug development. Our expert scientists can help determine effective dose curves for your molecules of interest in whole cell assays, whether they are small molecules or biologics, including antibody drug conjugates. Over 30 different tumor cell lines are available to model human tumor types, including lung, breast, ovarian, pancreatic, and colorectal carcinomas, leukemias, and lymphomas. You can also select primary cells such as PBMCs or iPSC-derived cells, or choose from our genetically engineered cell lines, overexpressing proteins of interest. We accurately measure cell viability, proliferation, and death using a robust ATP-dependent homogeneous assay that demonstrates high linearity from 100 to 200,000 cells per well in 96-well plates, capable of supporting high throughput capacity. Alternatively, cancer cells constitutively expressing luciferase can be used, providing a simple and rapid readout for cell numbers.

Small Molecule Cell Cytotoxicity Diagram

Cell-Dependent Cytotoxicity Assays

If the mechanism for cell-killing requires functional killer cells, we can also provide screening and profiling services to evaluate your drug candidates. Our expert scientists can screen your conventional antibodies, multi-specific antibodies, and bispecific T cell or NK cell engagers, using cytotoxic T cells and NK cells and the appropriate target expressing cells. We have a number of validated systems ready for use in screening assays, which include positive control antibodies and BiTEs. We can also develop custom target cells and custom assay systems to deliver the best results for your needs. Development, testing, and validation of CAR constructs are also available.

Request Quote

Learn more about the process and deliverables.

Available Cells for Testing

Tumor Cell Line

A2780, human ovarian carcinoma

A549, human lung carcinoma

BT-474, human breast adenocarcinoma

BxPC-3, human pancreatic carcinoma

Daudi, human B cell lymphoma

HCT116, human colorectal carcinoma

HeLa, human hepatocellular carcinoma

Jurkat, human acute T cell leukemia

MCF-7, human breast adenocarcinoma

MDA-MB-231, human breast adenocarcinoma

MDA-MB-468, human breast adenocarcinoma

MIA PaCa-2, human pancreatic carcinoma

NALM6, human acute lymphoblastic leukemia

Neuro2A, mouse neuroblastoma cell line

NIH:OVCAR-3, human ovarian carcinoma

PANC-1, human pancreatic carcinoma

PC-12, rat pheochromocytoma

Raji, human B cell lymphoma

SK-BR-3, human breast adenocarcinoma

SK-OV-3, human ovarian carcinoma

THP-1, human acute monocytic leukemia

U937, pro-monocytic, human histiocytic lymphoma

UTSCC5, human squamous cell carcinoma

UTSCC8, human squamous cell carcinoma

UTSCC9, human squamous cell carcinoma

UTSCC10, human squamous cell carcinoma

UTSCC14, human squamous cell carcinoma

UTSCC16A, human squamous cell carcinoma

UTSCC16B, human squamous cell carcinoma

UTSCC24A, human squamous cell carcinoma

*Cell line lists may not be comprehensive. Inquire with us for more information.